The European Commission (EC) has granted approval for a single-vial, fully liquid presentation of GSK's Menveo vaccine (MenACWY), designed to protect against invasive meningococcal disease (IMD ...
The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...
That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another $430 million. Pfizer has been something of an also-ran in the ...